Pfizer Gains on Three-Year Pharma Tariff Reprieve

26 days ago

Nora Melinda

"Pfizer is the second biggest gainer in the S&P 500 today. That's ticker PFE. Of course, we know this stock has really been in focus. Largely Trump involved today. So essentially, they are going to be getting a three-year reprieve, specifically as it relates to those pharma tariffs here."

Pfizer (PFE) is highlighted as a top mover with an intraday gain of approximately 6.7%. The commentary notes that a three-year tariff reprieve, achieved through political maneuvering, serves as a positive catalyst raising investor expectations.

Related Stocks